With a market cap of $124.4 billion, Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical company that discovers, develops, manufactures, and markets innovative medicines worldwide. Its portfolio spans key therapeutic areas including oncology, hematology, immunology, cardiovascular disease, and neuroscience, with well-known products such as Opdivo, Eliquis, Revlimid, and Yervoy. Companies valued at $10 billion or more are generally classified as “large-cap” stocks, and Bristol-Myers Squibb fi ...

Company Overview - Structure Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative oral therapeutics for chronic diseases, particularly targeting significant unmet medical needs [2][3] - The company specializes in G-protein-coupled receptor (GPCR) drug discovery, with a pipeline led by GSBR-1290 aimed at treating type-2 diabetes and obesity, as well as candidates for pulmonary and cardiovascular diseases [2] Financial Performance - As of the end of 2025, Structure Therapeutics reported a net loss of $141.2 million, with research expenditures reaching $225.3 million to advance its GLP-1 franchise, which is typical for companies preparing for late-stage trials [9] - The company ended 2025 with $1.4 billion in cash and investments, which is expected to fund operations through the end of 2028 [8] Stock Performance - Structure Therapeutics' shares were priced at $71.41 as of February 17, 2026, reflecting a 214.3% increase over the past year, significantly outperforming the S&P 500 by 180.87 percentage points [4] - Casdin Capital sold 380,000 shares of Structure Therapeutics during the fourth quarter, valued at approximately $15.52 million based on the average share price for that period [5][6] Clinical Developments - The company reported promising data from its Phase 2 ACCESS programs, showing placebo-adjusted weight loss of up to 15.3% at 36 weeks with higher doses of aleniglipron, with no plateau observed [8] - A 44-week readout is anticipated in the first quarter of 2026, and the initiation of Phase 3 trials is planned for the second half of 2026 [8] Market Position - Structure Therapeutics aims to provide differentiated treatment options that enhance both efficacy and patient convenience, positioning itself competitively within the evolving biopharmaceutical landscape [1]

Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or dose-limiting toxicities at three months Early signals of functional and structural improvement observed at one month and three months12-letter BCVA gain and 23% CST reduction observed in the treated eye at three monthsFull cohort data expected in mid-year 2026 RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Com ...

Amneal Pharmaceuticals (NasdaqGS:AMRX) Q4 2025 Earnings call February 27, 2026 08:30 AM ET Company ParticipantsAnastasios Konidaris - EVP and CFOAnthony DiMeo - Head of Investor RelationsChintu Patel - Co-Founder and Co-CEOChirag Patel - Co-Founder and Co-CEOChris Schott - Managing DirectorJoe Renda - SVP and Chief Commercial OfficerConference Call ParticipantsDavid Amsellem - Managing Director and Senior Research AnalystLeszek Sulewski - Research AnalystMatt Dellatorre - VP and Equity AnalystOperatorThank ...

Amneal Pharmaceuticals (NasdaqGS:AMRX) Q4 2025 Earnings call February 27, 2026 08:30 AM ET Company ParticipantsAnastasios Konidaris - EVP and CFOAnthony DiMeo - Head of Investor RelationsChintu Patel - Co-Founder and Co-CEOChirag Patel - Co-Founder and Co-CEOChris Schott - Managing DirectorJoe Renda - SVP and Chief Commercial OfficerConference Call ParticipantsDavid Amsellem - Managing Director and Senior Research AnalystLes Sulewski - AnalystMatt Dellatorre - VP and Equity AnalystOperatorThank you all for ...

CALABASAS, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced today announced that it will host an investor conference call and webcast on March 4, 2026, at 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time. During the call, members of the NeOnc management team and independent members of the Company’s S ...

The Harbor Capital Advisors released its “Mid Cap Value Fund’s” Q4 2025 investor letter. A copy of the letter can be downloaded here. Harbor Mid Cap Value Fund, subadvised by LSV Asset Management, delivered solid outperformance in the fourth quarter of 2025, with the Institutional Class returning 4.07% versus 1.42% for the Russell Midcap Value Index, benefiting from strength in value stocks as the Russell Midcap Growth Index declined 3.7% during the period. U.S. equities broadly advanced, with the S&P 500 ...

Core Insights - CG Oncology, Inc. reported financial results for Q4 and the full year 2025, highlighting a net loss of $161.0 million for the year, compared to a loss of $88.0 million in 2024, indicating increased operational costs and investments in R&D [12][14]. Financial Highlights - Cash and cash equivalents as of December 31, 2025, were $742.2 million, up from $680.3 million as of September 30, 2025, bolstered by net proceeds of approximately $98.4 million from shares sold in Q4 [5][8]. - R&D expenses for Q4 2025 were $30.0 million, an increase from $26.8 million in Q4 2024, with full-year R&D expenses totaling $116.6 million compared to $82.1 million in 2024 [12]. - G&A expenses for Q4 2025 were $18.0 million, up from $11.7 million in the prior year, with full-year G&A expenses reaching $73.5 million compared to $33.7 million in 2024 [12]. Clinical Development Updates - The company anticipates topline data from the PIVOT-006 Phase 3 trial evaluating cretostimogene in intermediate-risk NMIBC in the first half of 2026, which is nearly a year ahead of schedule [6][7]. - Results from the CORE-008 Cohort CX trial, assessing the combination of cretostimogene with gemcitabine in high-risk NMIBC, are also expected in the first half of 2026 [6][7]. - Cretostimogene has shown promising efficacy in previous trials, with high-grade event-free survival rates of 95.7%, 84.6%, and 80.4% at 3, 6, and 9 months, respectively, in high-risk BCG unresponsive NMIBC [7]. Corporate Developments - The company strengthened its Board of Directors by adding Christina Rossi, a life-science executive with extensive experience in commercial organizations and new medicine launches [7]. - CG Oncology has initiated an Expanded Access Program for cretostimogene in North America for patients unresponsive to BCG [9].

Core Insights - Polaryx Therapeutics is committed to developing disease-modifying therapies for rare pediatric lysosomal storage disorders (LSDs) and raising awareness within the rare disease community [2][4] Company Overview - Polaryx Therapeutics, founded in 2014, focuses on small molecule and gene therapy treatments for rare orphan LSDs, aiming to address significant unmet medical needs [8] - The company's lead candidate, PLX-200, is designed to target multiple LSDs and is currently advancing through clinical trials [8] Clinical Trials - The SOTERIA trial is a Phase 2, open-label, single-arm study aimed at evaluating the safety, tolerability, and clinical activity of PLX-200 across four rare LSDs: CLN2, CLN3, Krabbe disease, and Sandhoff disease [7] - The trial is expected to begin in the first half of 2026, with sites in the United States, Europe, and Asia [7] - SOTERIA is designed to be flexible and resource-efficient, potentially validating PLX-200's preclinical science while gathering important data for future clinical development [7] Rare Disease Context - LSDs are a group of over 50 inherited metabolic diseases caused by genetic mutations, affecting approximately 1 in 5,000 births [3][4] - The National Organization for Rare Diseases (NORD) defines a rare disease as one affecting fewer than 1 in 2,000 people globally, with about 70% starting in childhood [4] - More than 300 million people worldwide are affected by rare diseases, highlighting the urgent need for new treatments [4]

MIAMI, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Biotech on the Beach Summit, being held March 10-11, 2026, at 1 Hotel South Beach in Miami. Management will be holding one-on-one meetings with investors registered for the event on Wednesday, March 11th. Investors interested in scheduling a meeting with OPKO management should contact their Jefferies representative. About OPKO Health OPKO is a multinational biophar ...